Bharat Biotech has received approval to begin clinical trials in India of its COVID-19 vaccine candidate. The trial will be the first for a COVID vaccine developed in that country. Read More

Inovio Pharmaceuticals has released data from the phase 1 clinical trial of its COVID-19 vaccine candidate showing it was safe and well-tolerated and induced immune responses in a majority of participants. Read More

The University of Oxford is resuming recruitment this week for its global clinical trial of hydroxychloroquine and chloroquine, which was paused after a now-retracted study found the antimalarial drugs had no benefit as a treatment for COVID-19. Read More

FDA Commissioner Stephen Hahn said yesterday that he was “optimistic” that more than one COVID-19 treatment could be available by the fall in addition to Gilead Sciences’ remdesivir, which has already received Emergency Use Authorization from the agency. Read More

Any COVID-19 vaccine the FDA approves would have to be at least 50 percent more effective than a placebo, according to a new guidance it released yesterday. Read More

The University of Oxford is ready to launch a phase 3 trial in Brazil of AstraZeneca (AZ)’s COVID-19 vaccine candidate, considered by the World Health Organization (WHO) to be the frontrunner in the research race. Read More

After weeks of waiting, Gilead Sciences announced yesterday that it will charge U.S. insurers $3,120 for a six-vial, five-day course of remdesivir, and a lower price of $2,340 for governments of developed countries, including the U.S. Read More

The Coalition for Epidemic Preparedness Innovations (CEPI) has partnered with the Stevanato Group to help solve a serious problem facing vaccine manufacturers as they scale up production — a global shortage of glass vials. Read More

China has approved phase 1 trials of a COVID-19 vaccine candidate being developed by the country’s military in collaboration with two Chinese companies. Read More

The World Health Organization (WHO) has unveiled a plan to deliver 2 billion doses of COVID-19 vaccines to low- and middle-income countries by the end of 2021, but says it needs almost $28 billion to help fund the initiative, which also includes therapeutics and diagnostics. Read More